Tasly Pharmaceuticals, Inc. Participated in U.S. Government-Led Trade Mission to Support Regulatory Engagement and Global Development Strategy
Rockville, MD – March 16, 2023 – Tasly Pharmaceuticals, Inc. (“TPI”), a Maryland-based biopharmaceutical company, participated in the Trade Winds ASEAN Mission and Business Forum held March 13–15, 2023, in Bangkok, Thailand.
The Trade Winds program, organized by the U.S. Commercial Service within the U.S. Department of Commerce, represented a U.S. government-led trade mission and business development platform. The program facilitated engagement with commercial diplomats, regulatory stakeholders, and industry representatives from more than 20 countries across the ASEAN region.
During the forum, TPI engaged with regional stakeholders on regulatory science, clinical development frameworks, compliance considerations relevant to botanical and complex drug products, the business environment for cross-border collaboration, and discussions related to U.S. market opportunities, including SelectUSA-related investment dialogue.
TPI also presented information related to T89 (Dantonic®), a botanical drug candidate that had completed a U.S. Food and Drug Administration (FDA) Phase III global clinical trial. The discussion included an overview of the development approach, including clinical study design considerations, product quality standardization, and alignment with FDA botanical drug development guidance.
Participation in the Trade Winds program supported TPI’s efforts to enhance regulatory dialogue and to explore potential collaboration opportunities in areas such as co-development, clinical research, and licensing.
The Trade Winds ASEAN Mission and Business Forum was held at the Anantara and Avani Riverside Hotel in Bangkok, with programming conducted daily from approximately 8:00 a.m. to 8:30 p.m.
About Tasly Pharmaceuticals Inc.
Tasly Pharmaceuticals, Inc. is dedicated to advancing human health through safe and effective therapeutic solutions. The company focuses on the modernization of botanical medicines through scientific evaluation, including clinical and pharmacological research.
Founded in 2006 and based in Rockville, Maryland, TPI advances innovation in this field through scientific research, global collaboration, and integrated development initiatives.